TABLE 1.
Participant baseline demographics and disease characteristics.
| AZD9567 (n = 11) | Prednisolone (n = 10) | Overall (N = 21) | |
|---|---|---|---|
| Age, years | 64.5 (8.4) | 55.5 (13.6) | 60.2 (11.8) |
| Age group, years | |||
| 18–40 (%) | 0 | 2 (20.0) | 2 (9.5) |
| 41–65 (%) | 7 (63.6) | 6 (60.0) | 13 (61.9) |
| >65 (%) | 4 (36.4) | 2 (20.0) | 6 (28.6) |
| Female (%) | 8 (72.7) | 5 (50.0) | 13 (61.9) |
| White (%) | 11 (100) | 10 (100) | 21 (100) |
| Height, cm | 169.3 (9.4) | 171.0 (10.9) | 170.1 (9.9) |
| Weight, kg | 78.43 (13.28) | 80.67 (23.34) | 79.50 (18.29) |
| Years since onset of RA symptoms | 14.73 (14.59) | 13.35 (10.91) | 14.07 (12.67) |
| Years since RA diagnosis | 13.20 (15.24) | 12.79 (11.21) | 13.01 (13.14) |
| Presence of radiographic erosions (%) | 7 (63.6) | 5 (50.0) | 12 (57.1) |
| Rheumatoid factor positive (%) | 9 (81.8) | 9 (90.0) | 18 (85.7) |
| Functional capacity class (%) | |||
| Class I | 0 | 2 (22.2) | 2 (10.5) |
| Class II | 7 (70.0) | 5 (55.6) | 12 (63.2) |
| Class III | 3 (30.0) | 1 (11.1) | 4 (21.1) |
| Class IV | 0 | 1 (11.1) | 1 (5.3) |
| Previously treated with TNFα antagonist | 6 (54.5) a | 3 (30.0) | 9 (42.9) |
| Reason for TNFα antagonist discontinuation (%) | |||
| No response | 1 (20.0) | 1 (33.3) | 2 (25.0) |
| Subsequent loss of response | 2 (40.0) | 1 (33.3) | 3 (37.5) |
| Adverse effect/intolerance | 1 (20.0) | 1 (33.3) | 2 (25.0) |
| Other | 1 (20.0) | 0 | 1 (12.5) |
| DAS28‐CRP | 5.26 (0.98) | 4.90 (0.74) | 5.09 (0.87) |
| Comorbidities b (%) | |||
| Hypertension | 3 (27.3) | 4 (40.0) | 7 (33.3) |
| Hypothyroidism | 3 (27.3) | 1 (10.0) | 4 (19.0) |
| Hematuria | 0 | 3 (30.0) | 3 (14.3) |
| Concomitant medications (%) | |||
| Folic acid and derivatives | 8 (72.7) | 7 (70.0) | 15 (71.4) |
| Immunosuppressants, including methotrexate | 8 (72.7) | 7 (70.0) | 15 (71.4) |
| Anilides, including paracetamol/acetaminophen | 4 (36.4) | 3 (30.0) | 7 (33.3) |
| Nonsteroidal anti‐inflammatory and anti‐rheumatic agents, including hydroxychloroquine | 5 (45.5) | 2 (20.0) | 7 (33.3) |
Note: Data are n (%) or mean (SD).
Abbreviations: DAS28‐CRP, disease activity score in 28 joints with C‐reactive protein; RA, rheumatoid arthritis; SD, standard deviation; TNFα, tumor necrosis factor α.
a
One patient who was previously treated with TNFα antagonist continued treatment during the study.
b
Reported by at least three patients overall.